Madison Vaccines' Series A - II Round

Madison Vaccines raised a round of funding on March 10, 2015.

Madison Vaccines (MVI) is focused on the development of therapeutic plasmid DNA vaccine products for patients with prostate cancer. MVI is also developing a sensitivity test to identify those patients…

Articles about Madison Vaccines' Series A - II Round: